search for


Perioperative considerations of hyperthyroidism in a patient with liver failure: case report
Med Biol Sci Eng 2019;2(2):60-63
Published online July 31, 2019
© 2019 Medical Biological Science and Engineering.

Byung Hwa Kim, Yun Hee Kim, Yoon Sook Lee, Woon Young Kim, Jae Hwan Kim

Department of Anesthesiology and Pain Medicine, Ansan Hospital, Korea University College of Medicine, Ansan, Korea
Correspondence to: Jae Hwan Kim
Department of Anesthesiology and Pain Medicine, Ansan Hospital, Korea University College of Medicine, 123, Jeokgeum-ro, Danwon-gu, Ansan 15355, Korea
Tel: +82-31-412-5297
Fax: +82-31-412-5294
Received March 25, 2019; Revised May 13, 2019; Accepted May 14, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hyperthyroidism is one of the most common endocrinologic disorders. When patients with hyperthyroidism undergo general anesthesia, potential perioperative complications such as atrial fibrillation, congestive heart failure, ischemic heart disease, thrombocytopenia may occur. Hyperthyroidism treatment is mainly divided into three parts: Medical treatment, radioactive iodine therapy, and surgical removal of the thyroid. However, the previous two treatments may not have a significant effect on patients with liver failure. In this report, we present a case where a patient with an underlying disease of uncontrolled hyperthyroidism and liver failure undergoing liver transplantation, where preoperative thyroid levels couldn’t be managed aggressively due to liver failure. We managed hyperthyroidism using conservative management before and during surgery; perioperative use of steroids, beta-blockers, calcium channel-blockers, IV (Intravenous) fluids, body temperature regulation, opioid use such as remifentanil and fentanyl, sufficient sedation are all key in ensuring the hemodynamic stability of such a patient.
Keywords : Hyperthyroidism; Liver failure; Management
  1. Farling PA. Thyroid disease. Br J Anaesth 2000;85:15-28.
    Pubmed CrossRef
  2. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 2014;78:619-29.
    Pubmed CrossRef
  3. Wang R, Tan J, Zhang G, Zheng W, Li C. Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment. Medicine (Baltimore) 2017;96:e6035.
    Pubmed CrossRef
  4. Calissendorff J, Falhammar H. Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease. Endocr Connect 2017;6:200-5.
    Pubmed CrossRef
  5. Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ 2014;349:g5128.
    Pubmed CrossRef
  6. Gilbert J. Thyrotoxicosis - investigation and management. Clin Med (Lond) 2017;17:274-7.
    Pubmed CrossRef
  7. Palace MR. Perioperative management of thyroid dysfunction. Health Serv Insights 2017;10:1178632916689677.
    Pubmed CrossRef
  8. Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (N Y) 2011;7:337-9.
    Pubmed KoreaMed
  9. Lin TY, Shekar AO, Li N, Yeh MW, Saab S, Wilson M, et al. Incidence of abnormal liver biochemical tests in hyperthyroidism. Clin Endocrinol (Oxf) 2017;86:755-9.
    Pubmed CrossRef
  10. Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull 2015;5:1-11.
    Pubmed KoreaMed CrossRef
  11. Papachristos DA, Huynh J, Grossman M, MacIsaac RJ. Liver dysfunction and anti-thyroid therapy. SAGE Open Med Case Rep 2015;3:2050313X14568335.
    Pubmed CrossRef
  12. Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J 2016;63:1025-64.
    Pubmed CrossRef
  13. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 2014;35:808-17.
    Pubmed CrossRef
  14. Kim CW, Park JS, Oh SH, Park JH, Shim HI, Yoon JW, et al. Drug-induced liver injury caused by iodine-131. Clin Mol Hepatol 2016;22:272-5.
    Pubmed CrossRef
  15. Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease. Thyroid Res 2013;6:4.
    Pubmed CrossRef
  16. Suwansaksri N, Preechasuk L, Kunavisarut T. Nonthionamide drugs for the treatment of hyperthyroidism: from present to future. Int J Endocrinol 2018;2018:5794054.
    Pubmed CrossRef

July 2019, 2 (2)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)
  • Crossref
  • Google Scholar